Literature DB >> 2455184

Increased plasma norepinephrine and sympathetic nervous activity in essential hypertensive and uremic humans: effects of clonidine.

J L Izzo1, R P Santarosa, P S Larrabee, R J Smith, M C Kallay.   

Abstract

We investigated the relationship between hypertension and increased sympathoadrenal activity in previously normotensive, stable maintenance hemodialysis patients (uremics) who developed hypertension subsequent to the onset of chronic renal failure. In age-matched groups, supine morning plasma norepinephrine (NE) concentrations (pg/ml) were elevated in uremics (401 +/- 26, p less than 0.00001, n = 23) and essential hypertensives (340 +/- 23, p less than 0.01, n = 29) compared to normal controls (260 +/- 18, n = 24). To further investigate the functional significance of increased sympathoadrenal activity in uremia, a subset of dialysis patients was studied during chronic clonidine therapy. Compared to placebo baseline, clonidine (mean dose 0.4 mg/day) caused parallel decreases in mean arterial pressure (MAP) (-8 +/- 2 mm Hg, p less than 0.05), heart rate (HR) (-13 +/- 3 b/min, p less than 0.05), plasma NE (-84 +/- 13 pg/ml, p less than 0.01), and plasma epinephrine (-24 +/- 4 pg/ml, p less than 0.01). Clonidine exerted balanced effects on cardiac output and systemic vascular resistance while blood volume and plasma renin activity were slightly increased. We conclude that the increased sympathoadrenal activity in uremia contributes to chronically increased arterial pressure in a pattern similar to essential hypertension. Central sympatholytic drugs are effective antihypertensive agents in uremia.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2455184

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  1 in total

1.  Rhythmic oscillations of blood pressure and R-R interval in patients with chronic renal failure.

Authors:  M Munakata; Y Imai; H Sekino; K Abe
Journal:  Med Biol Eng Comput       Date:  1993-07       Impact factor: 2.602

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.